CD19 CAR T-cells for severe lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This early-phase trial tests whether a patient's own immune cells (T-cells) that are modified to target a protein called CD19 can help people with severe lupus that hasn't improved with other treatments. The goal is to reduce lupus activity and possibly achieve remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with lupus (SLE) that is still active despite trying at least two standard medications for at least 3 months each.
- Your blood tests show certain lupus antibodies (like anti-dsDNA) or a positive ANA test.
- Your heart, liver, and kidney function are within acceptable limits (e.g., no severe organ failure).
- You are not pregnant, not breastfeeding, and agree to use two forms of contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental treatment called CD19 UCAR T cells for people with severe lupus that hasn't gotten better with standard medicines. It aims to see if these special immune cells can safely and effectively control the disease.
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
This study tests a new treatment called CD19 CAR-T, which reprograms your own immune cells to attack lupus. It is for people with active lupus that has not responded well to standard therapies.
This trial tests whether a personalized cell therapy called CD19 CAR-T can help people with hard-to-treat lupus (SLE). The treatment uses your own immune cells that have been modified to attack faulty B cells, which are involved in lupus. It is for patients who have moderate to severe disease despite trying multiple standard treatments.
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
Hear when a new Systemic Lupus Erythematous (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.